Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Medicinal Chemistry, Pharmacology, and Potential Therapeutic Benefits of Cannabinoid CB2 Receptor Agonists
Mojgan Aghazadeh Tabrizi, Pier Giovanni Baraldi, Pier Andrea Borea, et al.
Chemical Reviews (2016) Vol. 116, Iss. 2, pp. 519-560
Open Access | Times Cited: 106

Showing 1-25 of 106 citing articles:

Breaking barriers to novel analgesic drug development
Ajay Yekkirala, David P. Roberson, Bruce P. Bean, et al.
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 8, pp. 545-564
Open Access | Times Cited: 313
Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus
Tarmo Nuutinen
European Journal of Medicinal Chemistry (2018) Vol. 157, pp. 198-228
Closed Access | Times Cited: 228
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Mauro Maccarrone, Vincenzo Di Marzo, Jürg Gertsch, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 5, pp. 885-958
Open Access | Times Cited: 83
Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders
Gemma Navarro, Paula Morales, Carmen Rodríguez‐Cueto, et al.
Frontiers in Neuroscience (2016) Vol. 10
Open Access | Times Cited: 134
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure–Functional Selectivity Relationships (SFSRs) and Therapeutic Potential
Liang Tan, Wenzhong Yan, John D. McCorvy, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 22, pp. 9841-9878
Closed Access | Times Cited: 120
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution
Samuel D. Banister, Mark Connor
Handbook of experimental pharmacology (2018), pp. 191-226
Closed Access | Times Cited: 115
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins
Samuel D. Banister, Mark Connor
Handbook of experimental pharmacology (2018), pp. 165-190
Closed Access | Times Cited: 87
Molecular Mechanism and Cannabinoid Pharmacology
Lesley D. Schurman, Dai Lu, Debra A. Kendall, et al.
Handbook of experimental pharmacology (2019), pp. 323-353
Open Access | Times Cited: 73
Challenges and Opportunities in Central Nervous System Drug Discovery
Jonathan J. Danon, Tristan A. Reekie, Michael Kassiou
Trends in Chemistry (2019) Vol. 1, Iss. 6, pp. 612-624
Open Access | Times Cited: 69
Type-2 cannabinoid receptors in neurodegeneration
Tiziana Bisogno, Sergio Oddi, Alessandra Piccoli, et al.
Pharmacological Research (2016) Vol. 111, pp. 721-730
Closed Access | Times Cited: 66
Cannabinoids for the treatment of rheumatic diseases — where do we stand?
Daphna Katz-Talmor, Itay Katz, Bat-Sheva Porat-Katz, et al.
Nature Reviews Rheumatology (2018) Vol. 14, Iss. 8, pp. 488-498
Closed Access | Times Cited: 55
Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications
Vivek S. Kumawat, Ginpreet Kaur
European Journal of Pharmacology (2019) Vol. 862, pp. 172628-172628
Closed Access | Times Cited: 46
Comparison of the Regenerative Metabolic Efficiency of Lipid Extracts from Microalgae Nannochloropsis oceanica and Chlorococcum amblystomatis on Fibroblasts
Anna Stasiewicz, Tiago Conde, M. Rosário M. Domingues, et al.
Antioxidants (2024) Vol. 13, Iss. 3, pp. 276-276
Open Access | Times Cited: 5
Molecular mechanisms and pharmacology of cannabinoids: from theory to practice
Marek Lapka
Klinická farmakologie a farmacie (2025) Vol. 38, Iss. 4, pp. 156-160
Open Access
Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure–Affinity Relationship (SAfiR) and Structure–Activity Relationship (SAR) Studies
Francesco Spinelli, Elena Capparelli, Carmen Abate, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 24, pp. 9913-9931
Open Access | Times Cited: 43
Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases
Cristina Prandi, Marco Blangetti, Dvora Namdar, et al.
Molecules (2018) Vol. 23, Iss. 7, pp. 1526-1526
Open Access | Times Cited: 42
Prediction of Orthosteric and Allosteric Regulations on Cannabinoid Receptors Using Supervised Machine Learning Classifiers
Yuemin Bian, Yankang Jing, Lirong Wang, et al.
Molecular Pharmaceutics (2019) Vol. 16, Iss. 6, pp. 2605-2615
Open Access | Times Cited: 40
Cannabinoids in Glaucoma Patients: The Never-Ending Story
Andrea Passani, Chiara Posarelli, Angela Tindara Sframeli, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 12, pp. 3978-3978
Open Access | Times Cited: 38
Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist
Hebaallah Mamdouh Hashiesh, Charu Sharma, Sameer N. Goyal, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 28
Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma
Alexandre Vallée, Yves Lecarpentier, Jean-Noël Vallée
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3798-3798
Open Access | Times Cited: 27
Cannabinoid CB2 receptor controls chronic itch by regulating spinal microglial activation and synaptic transmission
Kangtai Xu, Xuefei Liu, Qian Zeng, et al.
Cell Reports (2025) Vol. 44, Iss. 4, pp. 115559-115559
Open Access
Evaluation of carboxamide-type synthetic cannabinoids as CB1/CB2 receptor agonists: difference between the enantiomers
Takahiro Doi, Takaomi Tagami, Akihiro Takeda, et al.
Forensic Toxicology (2017) Vol. 36, Iss. 1, pp. 51-60
Open Access | Times Cited: 37
Anti-inflammatory activity of cannabinoid receptor 2 ligands in primary hPDL fibroblasts
Ammaar H. Abidi, Chaela S. Presley, Mustafa Kh. Dabbous, et al.
Archives of Oral Biology (2017) Vol. 87, pp. 79-85
Closed Access | Times Cited: 36
Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor
Silvia Marino, Aymen I. Idris
Pharmacological Research (2017) Vol. 119, pp. 391-403
Open Access | Times Cited: 33
Cannabinoid Receptor Type 2 Ligands: An Analysis of Granted Patents Since 2010
Benjamin Brennecke, Thais Gazzi, Kenneth Atz, et al.
Pharmaceutical Patent Analyst (2021) Vol. 10, Iss. 3, pp. 111-163
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top